TITLE

Is Longer Always Better?

PUB. DATE
May 2008
SOURCE
Hastings Center Report;May/Jun2008, Vol. 38 Issue 3, p10
SOURCE TYPE
Academic Journal
DOC. TYPE
Case Study
ABSTRACT
The article describes a case study aimed at developing a new treatment for avian influenza. The goal is to find ways of generating and collecting viral antibodies from the blood of healthy subjects after injecting them with an avian flu vaccine approved by the U.S. Food & Drug Administration. Side effects from the vaccine is the primary risks of participating in the study.
ACCESSION #
32727107

 

Related Articles

  • FDA Approves First US Avian Influenza Virus Vaccine.  // Pulmonary Reviews;May2007, Vol. 12 Issue 5, p14 

    The article reports on the approval of the first avian influenza virus vaccine for humans by the U.S. Food and Drug Administration. The vaccine manufactured by Sanofi Pasteur Inc. was obtained from a human strain and is intended for immunizing people 18 through 64 years of age at risk of...

  • MEDICINE IN THE NEWS. Asch-Goodkin, Judith; Kaplan, Deborah // Patient Care for the Nurse Practitioner;May2007, Vol. 10 Issue 5, p4 

    This section offers medical news briefs in the United States. The Infectious Diseases Society of America (IDSA) has issued new guidelines based on recent studies of travel-related illnesses. The U.S. Food and Drug Administration (FDA) has approved the bird flu vaccine to protect humans against...

  • Avian flu vaccine stockpiling continues. Johnsen, Michael // Drug Store News;11/7/2005, Vol. 27 Issue 15, p4 

    The article focuses on the stockpiling of avian flu vaccines in the United States. The federal government and the global pharmaceutical community is increasing its efforts to prepare for potential avian flu pandemic. The United States Food and Drug Administration has formed a rapid response team...

  • FDA moves to include more women in drug studies.  // Nation's Health;Oct97, Vol. 27 Issue 9, p4 

    Provides information on the proposal of US Food and Drug Administration (FDA) involving the right of young women to be part of clinical studies. Reason why drug companies excluded young women in drug studies; Expectation of FDA regarding the proposal.

  • FDA Promotes DMCs to Enhance Subject Safety. Wechsler, Jill // Applied Clinical Trials;Feb2002, Vol. 11 Issue 2, p20 

    Reports on the U.S. Food and Drug Administration's promotion of data monitoring committees (DMC) that will enhance the safety of human research subjects in clinical trials. Roles, responsibilities and operations of DMC; Increase in industry and government research collaborations; Increase in...

  • U.S. vaccine against bird flu approved.  // Nation's Health;Jun/Jul2007, Vol. 37 Issue 5, p8 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of the first vaccine against the H5N1 avian influenza virus in the country, manufactured by Sanofi Pasteur Inc. According to a clinical trial, fewer than half of the people vaccinated developed a protective level...

  • FDA Approves Sanofi Bird Flu Vaccine.  // Clinical Infectious Diseases;6/15/2007, Vol. 44 Issue 12, piv 

    The article reports on the approval of Food and Drug Administration (FDA) officials to a Sanofi-Aventis vaccine to prevent people from becoming infected with the H5NI bird flu virus in the U.S. On April 17, 2007, the U.S. health officials has approved the Sanofi bird flu vaccine after they have...

  • IN BRIEF.  // BMJ: British Medical Journal (International Edition);4/28/2007, Vol. 334 Issue 7599, p868 

    This article presents medical news briefs. The United States Food and Drug Administration has approved a human vaccine against the H5N1 influenza virus (bird flu). Medical Research Scotland is inviting applications for research projects on pain relief. Public prosecutors in the Netherlands have...

  • Spotlight on Clinical Research Prompts Oversight Changes. Wechsler, Jill // Applied Clinical Trials;Dec2000, Vol. 9 Issue 12, p19 

    Discusses changes in 2000 in personnel at the United States Food and Drug Administration (FDA) and National Institutes of Health (NIH). Continued public concern about the adequacy of protection for human subjects participating in clinical trials; Establishment of the Office of Human Research...

Share

Read the Article

Other Topics